JG
AKCA

Joel Greenblatt’s Akcea Therapeutics Inc AKCA Stock Holding History

Joel Greenblatt’s Portfolio AKCA Stock Details AKCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-18,189
Closed -$260K – 1250
2020
Q1 		$260K Buy
+18,189
New +$299K 0.01% 876
2019
Q3 		– Sell
-10,829
Closed -$254K – 1267
2019
Q2 		$254K Buy
+10,829
New +$267K ﹤0.01% 998

Other funds holding AKCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Joel Greenblatt's AKCA Position: Q2 2020 in Review

Joel Greenblatt sold out of Akcea Therapeutics Inc (AKCA) in Q2 2020, closing a stake of 18,189 shares — an estimated $260K sold.

Joel Greenblatt first reported a position in AKCA in Q2 2019 and held it in 2 quarters. The position peaked at $260K in Q1 2020. 84 funds tracked by Wall St. Rank hold AKCA as of Q2 2020.

  • Joel Greenblatt reported no remaining Akcea Therapeutics Inc position as of Q2 2020 after selling out during the quarter.
  • Joel Greenblatt sold 18,189 Akcea Therapeutics Inc shares in Q2 2020, an estimated $260K.
  • Joel Greenblatt first reported a position in Akcea Therapeutics Inc in Q2 2019 and held it in 2 quarters.
  • Joel Greenblatt's Akcea Therapeutics Inc position peaked at $260K in Q1 2020.
  • 84 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q2 2020.

Based on Gotham Asset Management's 13F filing for Q2 2020, filed 13 Aug 2020.